The Genentech Sales Pitch: Higher Values R Us
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite a blizzard, Genentech attracts more than 300 Wall Street analysts and investors to hear why Roche’s bid undervalues the biotech.
You may also be interested in...
Roche Checks Wallet As Important Avastin Trial Flops
After months of anticipation, Roche announced the results of a closely watched clinical trial showing that its Avastin (bevacizumab) medication failed to prevent the recurrence of early-stage colon cancer in patients who underwent surgery
Roche Checks Wallet As Important Avastin Trial Flops
After months of anticipation, Roche announced the results of a closely watched clinical trial showing that its Avastin (bevacizumab) medication failed to prevent the recurrence of early-stage colon cancer in patients who underwent surgery
Roche Checks Wallet As Important Avastin Trial Flops
Did Roche overpay for Genentech? Closely watched adjuvant trial for colon cancer fails to meet primary endpoint.